• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Point Of Views

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Intensified Biomanufacturing

Learn how Syngene is achieving three to four-fold higher titers of mAbs using its Intensified Fed-Batch process

Enabling early assessment of drug targets to maximize clinical and commercial success

Comprehensive diligence around a target at the start of a discovery program can make the difference between success and failure. Learn how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.

Essential In vivo Safety - Tox studies to move your molecule from Target to IND successfully

Learn about Syngene’s expertise in  Safety/Tox studies that allows us to guide you through the various requirements leading to successful IND submission.

DMPK strategies to avoid drug development mistakes early

Learn the DMPK strategies that have helped Syngene scientists avoid drug development mistakes early while driving cost-effective, reproducible, high-quality data for clients.

Accelerating PROTAC programs to drug the “undruggable”

Syngene offers expertise in all aspects of PROTACs – from designing of small molecules to their synthesis, lead optimization, and ultimate candidate delivery at an accelerated pace.

Achieving Biologics manufacturing milestones using a systemic approach to Technology Transfer

Learn how Syngene achieves manufacturing milestones in Biologics using a systemic approach to 100% ‘first-time right’ technology transfer.

 

Manufacturing vaccines during COVID-19

How and why CROs/CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.

Audit Syngene Virtually

Syngene is using virtual audits to enable clients/regulators experience its capability and infrastructure, without physically visiting the site.

Combating COVID-19 - The Oligonucleotide Way

Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.

Has the Age of Antisense Oligonucleotides Finally Arrived

Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details